Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4mutations in hypermutated tumors

The authors discuss future perspectives regarding the treatment of uveal melanoma (UM) and why the therapeutic regimen must be tailored to the biological tumor background.

Abstract

Metastatic uveal melanoma is a deadly disease with no proven standard of care. Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor. We identify additional tumors in The Cancer Genome Atlas (TCGA) cohorts with similar hypermutator profiles in patients carrying germline deleterious MBD4 mutations and somatic loss of heterozygosity. This MBD4-related hypermutator phenotype may explain unexpected responses to immune checkpoint inhibitors.

A digest of this paper is available here.

To download this paper, please click here.